Posted by Michael Wonder on 22 Jan 2020
Reimbursement for Repatha to expand treatment options for ASCVD patients
22 January 2020 - Amgen is set to expand treatment options for atherosclerotic cardiovascular disease patients with Repatha, a high-cholesterol treatment, after receiving insurance benefits for the drug, the company said Wednesday.
"The reimbursement for Repatha will be able to help lower LDL cholesterol in high-risk groups to prevent the recurrence of cardiovascular disease in patients when used in combination with statins and ezetimibe," said Professor Gwon Hyeon-cheol from the Department of Cardiology at Samsung Medical Center in a news conference Wednesday.
The company received reimbursement for the drug from the Ministry of Health and Welfare on 1 January in treating patients with ASCVD and hypercholesterolaemia patients with heterozygous familial hypercholesterolaemia and statin intolerance.
